Straits Times Index
3,297.50 +24.78 (+0.76%) Nikkei
38,460.08 +907.92 (+2.42%) Hang Seng
17,151.87 +322.94 (+1.92%) FTSE 100
8,075.13 +30.32 (+0.38%) Bitcoin USD
66,654.57 +409.82 (+0.62%) CMC Crypto 200
1,417.25 -6.85 (-0.48%)
CSL Limited (CMXHF)
| Previous close | 176.00 |
| Open | 176.00 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 176.00 - 176.00 |
| 52-week range | 144.81 - 207.67 |
| Volume | |
| Avg. volume | 254 |
| Market cap | 86.963B |
| Beta (5Y monthly) | 0.29 |
| PE ratio (TTM) | 34.58 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.46 (1.40%) |
| Ex-dividend date | 11 Mar 2024 |
| 1y target est | N/A |
- PR Newswire
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that the European Commission has granted conditional marketing authorization (CMA) for FILSPARI (sparsentan) for the treatment of adults with primary IgAN with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g). The CMA is granted for all member states of the European Union, as well as in Iceland, Liechtenstein and Norway.
- CNW Group
Ferinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure
CSL Vifor today announced that Health Canada has authorized Ferinject (ferric carboxymaltose) for the intravenous (IV) treatment of iron deficiency anemia in adult and pediatric patients one year of age and older when oral iron preparations are not tolerated or are ineffective, as well as for the treatment of iron deficiency in adult patients with heart failure and New York Heart Association (NYHA) class II/III* 1 to improve exercise capacity.2 Ferinject has now received marketing authorization
- PR Newswire
CSL Seqirus is Fully Prepared to Implement the FDA's Vaccines and Related Biological Products Advisory Committee Trivalent Influenza Vaccines Strain Selection for the 2024/25 U.S. Season
CSL Seqirus, a global leader in the protection of public health, confirmed it is fully prepared to deliver its influenza vaccine portfolio for the 2024/25 U.S. season, based on the trivalent strains recommended this week by the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC). During the meeting, the committee confirmed the viral strain selection of influenza vaccines for the Northern Hemisphere 2024/25 season, which aligns with the F
